ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1754

The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study

Elena Myasoedova1, John Davis1, Vanessa Kronzer1, Rachel Giblon1, Elizabeth Atkinson1 and Cynthia Crowson2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

Meeting: ACR Convergence 2020

Keywords: Disability, Epidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA), many patients do not achieve remission or full physical functioning. We have previously shown that patients with RA have a significantly higher prevalence of functional disability (FD) than non-RA subjects across RA disease duration, age and calendar time. However, the pattern of improvement or worsening of functional status in RA vs non-RA patients over time has not been studied. We aimed to assess time spent in FD and transition probability between different levels of FD in patients with RA vs the non-RA subjects after RA incidence/ index date.

Methods: This retrospective population-based cohort study included residents of a geographical area who met 1987 ACR criteria for RA in 1999-2013 and a cohort of non-RA subjects from the same area matched by age and sex. Index date was RA incidence date for RA subjects and incidence date of the matching RA patient for non-RA subjects. Activities of Daily Living (ADL) were recorded annually since 1999 based on patient provided information about performing 6 ADLs without assistance: feeding oneself, dressing, using the toilet, bathing, walking and housekeeping. FD was defined as having difficulty with ≥1 of the 6 ADLs. Changes in the number of disabilities were considered to be state transitions. Multi-state modeling was used to estimate the probability of transitioning between FD states, with death as a final state. Cox models of multistate data were used to assess the risk of transition with 95 percent confidence intervals (CI) between the levels of FD, adjusting for age, sex, calendar year of index, smoking, and obesity.

Results: A total of 558 patients with RA (mean age 55.4 years, 71% females, 64% RF/CCP positive) and 457 non-RA subjects (mean age 56.5, 70% females) completed 6,594 questionnaires (3,875 RA and 2,719 non-RA) from 1/5/1999 to 1/5/2018 on or after index date. Figure 1 shows probability of FD in RA vs non-RA patients after the index date. In the first 15 years of disease, patients with RA expect to spend 10.1 years without FD and 1.7 years with 1 FD vs 11.6 years (p< 0.001) and 0.9 years (p< 0.001) in non-RA subjects, respectively. Probability of no FD at index is 78% in RA and 92% in non-RA. By 10 years after index date, probability of no FD in RA is 65%; probability of 1 disability 11%; 2 disabilities 6%, and >3 disabilities 1%, compared to 73%; 7%; 5% and 1% in the non-RA subjects, respectively. Risk of transitioning from no FD to FD is significantly higher in RA vs non-RA subjects: Hazard Ratio (HR) 2.4; 95%CI 1.9-3.0. Patients with RA and non-RA subjects have similar risk of returning from FD to no FD (HR 1.2; 95%CI 0.93-1.6). Results did not differ by RF/CCP status.

Conclusion: Patients with RA have a significantly higher probability of any level of FD over RA disease duration, less time spent with no FD, and a 2-fold increased risk of transitioning from no FD to FD, but a similar risk of transitioning back to normal functional status during RA disease course compared to their non-RA counterparts. Our findings suggest that in the era of advanced therapeutics for RA disease management, FD remains an area of ongoing concern, leaving an ample room for improvement of functional outcomes in RA.

Figure 1. Probability of functional disability in 558 rheumatoid arthritis (RA) versus 457 non-RA patients after RA incidence/ index date


Disclosure: E. Myasoedova, None; J. Davis, Pfizer, 2, AbbVie, 5, 8, Sanofi-Genzyme, 5, 8; V. Kronzer, None; R. Giblon, None; E. Atkinson, None; C. Crowson, Myriad Genetics, 1, Pfizer, 1.

To cite this abstract in AMA style:

Myasoedova E, Davis J, Kronzer V, Giblon R, Atkinson E, Crowson C. The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/the-point-of-no-return-functional-disability-in-patients-with-rheumatoid-arthritis-versus-the-general-population-results-from-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-point-of-no-return-functional-disability-in-patients-with-rheumatoid-arthritis-versus-the-general-population-results-from-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology